Co-existence of renovascular hypertension, polyarteritis nodosa, antiphospholipid syndrome and methylenetetrahydrofolate reductase mutation

Pediatrics International

Volumn 55, Issue 4, 2013, Pages

  Yildiz, Bilal ^a   Cetin, Nuran ^a   Kural, Nurdan ^a   Kaya, Tamer ^a   Akcar, Nevbahar ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

antiphospholipid syndrome; methylenetetrahydrofolate reductase mutations; polyarteritis nodosa; renovascular hypertension

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALDOSTERONE; AMLODIPINE; CAPTOPRIL; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; LIPOPROTEIN A; PREDNISOLONE; PROPRANOLOL; RENIN;

ABDOMINAL PAIN; ADOLESCENT; ANTIHYPERTENSIVE THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL STENT; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; CASE REPORT; DIZZINESS; GENE MUTATION; HEADACHE; HUMAN; HYPERTENSION RETINOPATHY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MICROANEURYSM; MIDDLE CEREBRAL ARTERY OCCLUSION; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PERIPHERAL NEUROPATHY; POLYARTERITIS NODOSA; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION;

ANTIPHOSPHOLIPID SYNDROME; METHYLENETETRAHYDROFOLATE REDUCTASE MUTATIONS; POLYARTERITIS NODOSA; RENOVASCULAR HYPERTENSION;

ADOLESCENT; ANGIOGRAPHY; ANTIPHOSPHOLIPID SYNDROME; DNA; HUMANS; HYPERTENSION, RENOVASCULAR; MAGNETIC RESONANCE IMAGING; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; POLYARTERITIS NODOSA;

EID: 84881450307     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/ped.12135     Document Type: Article

References (10)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006; 4: 295-306.
2. Pereira BA, Silva NA, Ximenes AC, Alvarenga SL, Barbosa VS,. Cutaneous polyarteritis nodosa in a child with positive antiphospholipid and P-ANCA. Scand. J. Rheumatol. 1995; 24: 386-388.
3. Ozen S, Pistorio A, Iusan SM, et al. Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann. Rheum. Dis. 2010; 69: 798-806.
4. Han BK, Inaganti K, Fahmi S, Reimold A,. Polyarteritis nodosa complicated by catastrophic antiphospholipid syndrome. J. Clin. Rheumatol. 2004; 10: 210-213.
5. Avcin T,. Antiphospholipid syndrome in children. Curr. Opin. Rheumatol. 2008; 20: 595-600.
6. Hansen KE, Moore KD, Ortel TL, et al. Antiphospholipid antibodies in patients with Wegener's granulomatosis and polyarteritis nodosa. Arthritis Rheum. 1999; 42: 2250-2252.
7. Zetterberg H, Coppola A, D'Angelo A, et al. No association between the MTHFR A1298C and transcobalamin C776G genetic polymorphisms and hyperhomocysteinemia in thrombotic disease. Throm. Res. 2002; 108: 127-131.
8. Freitas AI, Mendonça I, Guerra G, et al. Methylenetetrahydrofolate reductase gene, homocysteine and coronary artery disease: The A1298C polymorphism does matter. Inferences from a case study (Madeira, Portugal). Thromb. Res. 2008; 122: 648-656.
9. Hsieh Wu J,. Lipoprotein(a) in vascular disease, cancer and longevity. Chang Gung Med. J. 2011; 34: 555-564.
10. Korte W, Greiner J, Feldges A, Riesen WF,. Increased lipoprotein(a) levels are not a steady prothrombotic defect. Blood 2001; 98: 1993-1994.